VEA
MRTX

Virtus ETF Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Virtus ETF Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,684
Closed -$117K – 469
2023
Q3 		$117K Sell
2,684
-268
-9% -$9.57K 0.07% 322
2023
Q2 		$107K Buy
2,952
+634
+27% +$26.1K 0.06% 352
2023
Q1 		$86.2K Sell
2,318
-885
-28% -$39.8K 0.05% 372
2022
Q4 		$145K Buy
3,203
+1,214
+61% +$78.6K 0.08% 354
2022
Q3 		$139K Buy
1,989
+14
+0.7% +$1.04K 0.06% 365
2022
Q2 		$133K Buy
1,975
+861
+77% +$54.8K 0.05% 344
2022
Q1 		$92K Sell
1,114
-69
-6% -$7.06K 0.04% 317
2021
Q4 		$174K Sell
1,183
-66
-5% -$10.2K 0.07% 267
2021
Q3 		$221K Sell
1,249
-69
-5% -$11.1K 0.1% 242
2021
Q2 		$213K Buy
1,318
+40
+3% +$6.42K 0.09% 302
2021
Q1 		$219K Buy
1,278
+22
+2% +$4.36K 0.09% 313
2020
Q4 		$276K Sell
1,256
-1,764
-58% -$381K 0.11% 262
2020
Q3 		$501K Sell
3,020
-404
-12% -$55.3K 0.26% 138
2020
Q2 		$391K Buy
3,424
+213
+7% +$20.7K 0.19% 206
2020
Q1 		$247K Sell
3,211
-467
-13% -$41.9K 0.1% 253
2019
Q4 		$474K Buy
3,678
+988
+37% +$95.3K 0.08% 210
2019
Q3 		$210K Sell
2,690
-149
-5% -$14K 0.04% 238
2019
Q2 		$292K Sell
2,839
-3,667
-56% -$285K 0.06% 228
2019
Q1 		$477K Sell
6,506
-778
-11% -$52.9K 1.01% 31
2018
Q4 		$309K Sell
7,284
-2,291
-24% -$91.3K 0.05% 102
2018
Q3 		$451K Sell
9,575
-6,854
-42% -$382K 0.05% 139
2018
Q2 		$810K Sell
16,429
-26,707
-62% -$1.01M 0.72% 24
2018
Q1 		$1.32M Buy
43,136
+23,350
+118% +$648K 1.15% 11
2017
Q4 		$361K Buy
+19,786
New +$307K 0.45% 75
2016
Q2 		– Sell
-7,828
Closed -$168K – 153
2016
Q1 		$168K Buy
+7,828
New +$175K 0.23% 109

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Virtus ETF Advisers's MRTX Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 2,684 shares — an estimated $117K sold.

Virtus ETF Advisers first reported a position in MRTX in Q1 2016 and held it in 25 quarters. The position peaked at $1.32M in Q1 2018. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,684 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $117K.
  • Virtus ETF Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2016 and held it in 25 quarters.
  • Virtus ETF Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $1.32M in Q1 2018.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.